Janssen buys licence to diabetes and obesity drugs from Hanmi
pharmafile | November 10, 2015 | News story | Manufacturing and Production, Research and Development |Â Â Janssen, diabetes, hanmiÂ
Janssen could spend up to a billion dollars to buy for novel clinical stage biologics to treat diabetes and obesity.
The firm has obtained the worldwide global license and development rights to develop and commercialise oxyntomodulin-based therapies including HM12525A, a biologic that is completing Phase I clinical trials and which is expected to enter Phase II studies next year from Hanmi Pharmaceutical. The deal, which is potentially worth up to $915 million, will boost Janssen’s metabolism portfolio.
HM12525A is an oxyntomodulin-based therapy that has shown evidence of improving metabolic factors that lead to improved blood glucose, body weight, and insulin sensitivity. The drug has the potential, as a once weekly therapy, to be a best-in-class oxyntomodulin-based therapy, the companies say.
James List, global therapeutic area head of cardiovascular and metabolism at Janssen says: “We are very excited about this agreement with Hanmi and the potential of HM12525A to improve therapeutic options for people living with metabolic diseases
“Our deep scientific expertise and demonstrated clinical development capabilities support our commitment to aggressively develop and launch transformational therapies for patients with cardiovascular and metabolic diseases. We look forward to developing this potential best-in-class therapy, which allows us to build on our success in diabetes and strengthen our metabolism portfolio.”
Previously, Hamni licenced rights to its experimental GLP-1-RA agonist efpeglenatide to Sanofi as part of a deal potentially worth up to $4.2 billion. The agreement includes a weekly insulin and fixed-dose weekly GLP-1-RA insulin drug combination.
Yasmita Kumar
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
